<SUBMISSION>
<ACCESSION-NUMBER>0000950123-09-035840
<TYPE>8-K
<PUBLIC-DOCUMENT-COUNT>3
<PERIOD>20090814
<ITEMS>2.02
<ITEMS>9.01
<FILING-DATE>20090817
<DATE-OF-FILING-DATE-CHANGE>20090817
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>RXI PHARMACEUTICALS CORP
<CIK>0001390478
<ASSIGNED-SIC>2834
<IRS-NUMBER>000000000
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>8-K
<ACT>34
<FILE-NUMBER>001-33958
<FILM-NUMBER>091019306
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>60 PRESCOTT  STREET
<CITY>WORCESTER
<STATE>MA
<ZIP>01605
<PHONE>508-767-3861
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>60 PRESCOTT  STREET
<CITY>WORCESTER
<STATE>MA
<ZIP>01605
</MAIL-ADDRESS>
</FILER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>b76890rxe8vk.htm
<DESCRIPTION>RXI PHARMACEUTICALS CORPORATION
<TEXT>
<HTML>
<HEAD>
<TITLE>e8vk</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>






<DIV align="center" style="font-size: 14pt; margin-top: 12pt"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</B>
</DIV>

<DIV align="center" style="font-size: 12pt"><B>WASHINGTON, D.C. 20549</B>
</DIV>

<DIV align="center" style="font-size: 12pt"><B><DIV align="center"><DIV style="font-size: 3pt; margin-top: 16pt; width: 26%; border-top: 1px solid #000000">&nbsp;</DIV></DIV></B>
</DIV>

<DIV align="center" style="font-size: 18pt; margin-top: 12pt"><B>FORM 8-K</B>
</DIV>


<DIV align="center" style="font-size: 12pt; margin-top: 12pt"><B>CURRENT REPORT<BR>
PURSUANT TO SECTION 13 OR 15(D) OF THE<BR>
THE SECURITIES EXCHANGE ACT OF 1934</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>Date of report (Date of earliest event reported): August&nbsp;14, 2009</B></DIV>

<DIV align="center" style="font-size: 24pt; margin-top: 12pt"><B><FONT style="border-bottom: 1px solid #000000">RXI PHARMACEUTICALS CORPORATION</FONT></B>
</DIV>

<DIV align="center" style="font-size: 10pt">(Exact name of registrant as specified in its charter)</DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top">Delaware
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">001-33958
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">20-8099512</TD>
</TR>
<TR style="font-size: 1px">
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">(State or other jurisdiction of
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(Commission
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(I.R.S. Employer</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">of incorporation or organization)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">File Number)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Identification No.)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt">60 Prescott Street, Worcester, MA 01605</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 0pt"><DIV style="margin-top: 1px"><FONT style="border-top: 1px solid #000000">(Address of Principal Executive Offices) (Zip Code)</FONT></DIV></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt">Registrant&#146;s telephone number, including area code: (508)&nbsp;767-3861</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; text-indent: 2%">Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (<I>see </I>General Instruction A.2. below):
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Written communications pursuant to Rule&nbsp;425 under the Securities Act
(17 CFR 230.425)</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act
(17 CFR 240.14a-12)</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act
(17 CFR 240.14d-2(b))</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act
(17 CFR 240.13e-4(c))</TD>
</TR>

</TABLE>
</DIV>

<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>





<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<!-- TOC -->
<A name="toc"><DIV align="CENTER" style="page-break-before:always"><U><B>TABLE OF CONTENTS</B></U></DIV></A>

<P><CENTER>
<TABLE border="0" width="90%" cellpadding="0" cellspacing="0">
<TR>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="76%"></TD>
</TR>
<TR><TD colspan="9"><A HREF="#000">Item&nbsp;2.02 Results of Operations and Financial Condition</A></TD></TR>
<TR><TD colspan="9"><A HREF="#001">Item&nbsp;9.01 Financial Statements and Exhibits</A></TD></TR>
<TR><TD colspan="9"><A HREF="#002">Signature</A></TD></TR>
<TR><TD colspan="9"><A HREF="#003">Index to Exhibits</A></TD></TR>
<TR><TD colspan="9"><A HREF="b76890rxexv99w1.htm">Press Release dated August 14, 2009</A></TD></TR>
</TABLE>
</CENTER>
<!-- /TOC -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>




<!-- link1 "Item&nbsp;2.02 Results of Operations and Financial Condition" -->
<DIV align="left"><A NAME="000"></A></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Item&nbsp;2.02 Results of Operations and Financial Condition.</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On August&nbsp;14, 2009, RXi Pharmaceuticals Corporation issued a press release announcing its
financial results for the second quarter ended June&nbsp;30, 2009 a copy of which is attached as Exhibit
99.1 to this Current Report and incorporated herein by reference.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The information being furnished under Item&nbsp;2.02 in this Form 8-K, including the accompanying
exhibits, shall not be deemed to be &#147;filed&#148; for the purposes of Section&nbsp;18 of the Securities and
Exchange Act of 1934 (the &#147;Exchange Act&#148;), or otherwise subject to the liability of such section,
nor shall such information be deemed incorporated by reference in any filing under the Securities
Act of 1933 or the Exchange Act, regardless of the general incorporation language of such filing,
except as shall be expressly set forth by specific reference in such filing.
</DIV>
<!-- link1 "Item&nbsp;9.01 Financial Statements and Exhibits" -->
<DIV align="left"><A NAME="001"></A></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Item&nbsp;9.01 Financial Statements and Exhibits.</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(d)&nbsp;Exhibits
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">99.1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Press Release issued by RXi Pharmaceuticals Corporation on August&nbsp;14, 2009.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<!-- link1 "Signature" -->
<DIV align="left"><A NAME="002"></A></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Signature</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="52%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="13%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">RXI PHARMACEUTICALS CORPORATION<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">Date:  August 17, 2009&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Stephen J. DiPalma
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">Stephen J. DiPalma&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">Chief Financial Officer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<!-- link1 "Index to Exhibits" -->
<DIV align="left"><A NAME="003"></A></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Index to Exhibits</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="5%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="93%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Exhibit No.</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Description</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">99.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Press Release issued by RXi Pharmaceuticals Corporation on August&nbsp;14, 2009.</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>b76890rxexv99w1.htm
<DESCRIPTION>PRESS RELEASE DATED AUGUST 14, 2009
<TEXT>
<HTML>
<HEAD>
<TITLE>exv99w1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;99.1</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><IMG src="b76890rxb7689001.gif" alt="(RXI LOGO)">
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>RXi Pharmaceuticals Reports Financial Results for the Second Quarter of 2009</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Worcester, MA, August&nbsp;14, 2009 &#151; </B>RXi Pharmaceuticals Corporation (Nasdaq: RXII), a
biopharmaceutical company pursuing the development and commercialization of proprietary
therapeutics based on RNA interference (RNAi), today reported results for the quarter ended June
30, 2009.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Tod Woolf, Ph.D., President and Chief Executive Officer of RXi, commented, &#147;RXi continues to make
significant progress on its RNAi therapeutic platform with advances in research that have the
potential to address multiple large therapeutic markets with unmet medical needs. With the
financing that we recently closed, the Company is well positioned to continue its research with
cutting-edge RNAi technologies and therapeutic developmental programs, continuing its leadership
position in the RNAi therapeutics field.&#148;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><U><I>Corporate Highlights:</I></U>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>RXi exercised its option to an exclusive worldwide license to proprietary self-delivery
RNAi technology from Advirna LLC &#151; RXi&#146;s assessment of this novel technology indicated
that it could enable the delivery of RNAi molecules to cells spontaneously upon direct
administration, both <I>in vitro </I>and <I>in vivo</I>, without requiring a delivery vehicle or
transfection formulation. The ability to create self-delivering RNAi therapeutics may
potentially provide significant competitive advantages in efficacy, toxicity, ease of
administration and manufacturing cost. RXi has integrated this technology into its
comprehensive delivery platform to develop a sustainable pipeline of products for unmet
medical needs.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>$8 Million Public Offering &#151; RXi raised $8&nbsp;million in a public offering to institutional
investors that will be used for working capital and for general corporate purposes.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><U><I>Scientific Achievements: </I></U>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">RXi presented data at various key scientific conferences this quarter.
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Data on self-delivering rxRNA (sd-rxRNA&#153;) was presented at the TIDES Oligonucleotide
and Peptide<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> Technology and Product Development Conference and IBC&#146;s Drug Discovery and
Development conference.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Promising pre-clinical results from our self-delivering rxRNA (sd-rxRNA&#153;) were
presented demonstrating that sd-rxRNA promotes spontaneous cellular uptake of RNAi
therapeutics <I>in vitro</I>. In addition, RXi presented <I>in vivo </I>data that demonstrates that
sd-rxRNAs not only enter liver cells (hepatocytes)&nbsp;spontaneously, but also that
sd-rxRNAs significantly improve the biodistribution of RNAi compounds to the liver.
This positive data demonstrate the potential utility of RXi&#146;s sd-rxRNA&#153; compounds for
both local and subcutaneous
administration, which could allow a broad range of new areas of RNAi therapeutic
development.</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><U><I>Financial Highlights:</I></U>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The Company reported a net loss of $9.3&nbsp;million, or $0.67 per share, for the six months ended June
30, 2009, compared to a net loss of $7.0&nbsp;million, or $0.55 per share, for the same period in 2008.
The Company had 13,821,910 common shares outstanding at June&nbsp;30, 2009, as compared to 13,763,231
common shares outstanding at June&nbsp;30, 2008.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Research and development expenses for the six months ended June&nbsp;30, 2009 were $4.4&nbsp;million,
including approximately $1.4&nbsp;million in stock based compensation, compared to $3.9&nbsp;million
including $1.7&nbsp;million in stock-based compensation, for the six months ended June&nbsp;30, 2008. The
increase of approximately $0.5&nbsp;million, or 12.8%, was primarily due to higher staff-related costs
resulting from growth in R&#038;D staff and increased patent application and prosecution expenses,
coupled with a decrease of approximately $0.2&nbsp;million in stock-based compensation. General and
administrative expenses for the six months ended June&nbsp;30, 2009 were $4.8&nbsp;million, including $0.9
million in stock based compensation, compared to $3.2&nbsp;million, including $0.8&nbsp;million in stock
based compensation, for the six months ended June&nbsp;30, 2008. The increase of $1.6&nbsp;million, or 50.0%,
was primarily due to non-cash expense totaling $1.1&nbsp;million associated with warrants issued for
business advisory services and common stock issued pursuant to Standby Equity Distribution
Agreement (SEDA)&nbsp;that the Company entered into in January&nbsp;2009.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">As of June&nbsp;30, 2009, cash and cash equivalents totaled $4.4&nbsp;million, compared to cash and cash
equivalents of $9.9&nbsp;million at December&nbsp;31, 2008. This decrease is due to cash used in operations
of $5.5&nbsp;million for the six months ended June&nbsp;30, 2009. On July&nbsp;31, 2009 the Company entered into
a definitive agreement for the purchase of 2,385,715 shares of its common stock at $3.50 per share,
and warrants to purchase up to 954,286 shares of common stock at an exercise price of $4.50 per
share which will be exercisable beginning on February&nbsp;4, 2010. The offering closed on August&nbsp;4,
2009. The Company received approximately $7.8&nbsp;million in net proceeds from the offering. Proceeds
from the transaction will be used to meet working capital needs and for general corporate purposes.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>About RXi Pharmaceuticals Corporation</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">RXi Pharmaceuticals is a discovery-stage biopharmaceutical company pursuing the development and
potential commercialization of proprietary therapeutics based on RNA interference (RNAi) for the
treatment of human diseases. RXi Pharmaceuticals has a comprehensive RNAi platform that includes
both RNAi compounds and delivery methods. RXi Pharmaceuticals&#146; rxRNA&#153; compounds are distinct from
the siRNA compounds used by many other companies developing RNAi therapeutics and are very active
and potent (10-100 pM activity in cell culture) based on the company&#146;s internal research, in
addition to being nuclease resistant and readily manufactured. RXi Pharmaceuticals believes it is
well positioned to compete successfully in the RNAi-based therapeutics market with its accomplished
scientific advisors, including Dr.&nbsp;Craig Mello,
recipient of the 2006 Nobel Prize for his co-discovery of RNAi; a management team that is
experienced in developing RNAi products; and a strong early intellectual property position in RNAi
chemistry and delivery. <u>www.rxipharma.com</u>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Forward-Looking Statements</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">This press release contains forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about
future expectations, plan and future development of RXi Pharmaceutical Corporation&#146;s products and
technologies. These forward-looking statements about future expectations, plans and prospects of
the
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">development of RXi Pharmaceutical Corporation&#146;s products and technologies involve significant
risks, uncertainties and assumptions, including the risk of delays in satisfying the conditions to
selling any of the securities to YA Global Investments pursuant to the Standby Equity Distribution
Agreement that we have in place with them and the potential adverse impact on the market price of
our securities due to resale by YA Global Investments of securities purchased from the Company if
the Company sells them securities, the risk that the proceeds from the recently completed
securities offering will be insufficient to meet all of the capital needed to support our
operations, the risk that pre-clinical results of our oral delivery technology obtained to date may
not be reproducible in subsequent pre-clinical or clinical trials, the risk that unanticipated
safety or efficacy issues may arise in the course of developing our oral delivery technology, the
risk that the development of our RNAi-based therapeutics may be delayed or may not proceed as
planned and we may not be able to complete development of any RNAi-based product, the risk that the
FDA approval process may be delayed for any drugs that we develop, risks related to development and
commercialization of products by our competitors, risks related to our ability to control the
timing and terms of collaborations with third parties <I>and </I>the possibility that other companies or
organizations may assert patent rights that prevent us from developing our products. Actual results
may differ materially from those RXi Pharmaceuticals Corporation contemplated by these
forward-looking statements. RXi Pharmaceuticals Corporation does not undertake to update any of
these forward-looking statements to reflect a change in its views or events or circumstances that
occur after the date of this release.
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt">RXi Pharmaceuticals Corporation<BR>
(A Development Stage Company)
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">Condensed Statements of Expenses<BR>
(in thousands, except share and per share data)<BR>
(Unaudited)

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="52%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">For the Three</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">For the Three</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">For the Six</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">For the Six</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">Months Ended</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">Months Ended</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">Months Ended</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">Months Ended</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">June 30,</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">June 30,</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">June 30,</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">June 30,</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000">2009</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000">2008</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000">2009</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000">2008</TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Research and development
expense</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">3,026</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">2,766</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">4,442</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">3,854</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">General and administrative
expense</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,049</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,580</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4,804</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,213</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Operating loss</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(5,075</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(4,346</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(9,246</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(7,067</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Other income (expense), net</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(6</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">28</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(6</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">103</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Net loss</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(5,081</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(4,318</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(9,252</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(6,964</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Net loss per common share:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Basic and diluted loss per
share</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(0.37</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(0.34</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(0.67</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(0.55</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Weighted average common
shares outstanding:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Basic and diluted</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">13,812,817</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">12,743,404</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">13,812,367</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">12,713,918</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">RXi Pharmaceuticals Corporation<BR>
(A Development Stage Company)
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">Condensed Balance Sheets<BR>
(in thousands, except share and per share data)<BR>
(Unaudited)

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="76%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">June 30,</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">December 31,</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000">2009</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000">2008</TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Cash and cash equivalents</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">4,362</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">9,856</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Prepaid expenses and other current assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">333</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">73</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Equipment and furnishings, net</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">391</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">414</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Deposits</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">16</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">16</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<tr style="font-size: 10pt">
<TD>&nbsp;</TD>
</tr>

<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Total assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">5,102</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">10,359</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Accounts payable</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">580</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">394</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Accrued expense and other current liabilities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,274</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">976</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Current maturities of capital lease obligations</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">14</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">17</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Total current liabilities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,868</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,387</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Capital lease obligations, net of current maturities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">11</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Total liabilities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,879</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,391</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Total stockholders&#146; equity</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,223</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">8,968</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><tr style="font-size: 10pt">
<TD>&nbsp;</TD>
</tr>

<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Total liabilities and stockholders&#146; equity</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">5,102</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">10,359</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>CONTACT:</B><BR>
RXi Pharmaceuticals<BR>
Donna Falcetti<BR>
508-929-3615<BR>
ir@rxipharma.com

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">or

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Investors<BR>
SAN Group<BR>
Susan Noonan<BR>
212-966-3650<BR>
susan@sanoonan.com

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">or

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Media<BR>
Rx Communications Group<BR>
Eric Goldman<BR>
917-322-2563<BR>
egoldman@rxir.com

</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>b76890rxb7689001.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 b76890rxb7689001.gif
M1TE&.#EA.P!%`.8``'H<?G9V<74D>I2.DNCBY\.9O?KZ^>+6X:AXI]C9U;FI
MMH="ATY12EI74]C$U91WE'<>?=[1W(X^C."HT?7R\_W^_7XWA/;K\7H9?]FZ
MU?GR]G=%>LJ;PX5CAY=FEU%12Y=6EH=8B6DI:[V1N<6HPO/E[74V>E)21?S]
M^OC[]5)22_7X]+B(M8!&@E).2JN$JZ9HH\C(Q?O\^>_8Y]&FR?GV^'@L?%12
M24U,1U112]*RSLBTQMVESZ"0G91.EK![K5!51V\D<WP6?X`8@)UPG:51GK:W
MLX]3D5]767,?>+9\L/OY^I]XH/#O[5=.496<D&@<:_?Z^7`<=82"?_O\_+*6
ML=_?W5943HA.BHQAD&4T;91<D^3(WGD=>(]$CUA33G`O<Y)OD*"@G5)33:1>
MG[&LK%162JBEHG88?6AF8EE94?O[^]33T?S\_/CW]YQ?G,!_M,_.S;.QKLC(
MO&\<;G`]<\_0RJ&$H>OU[*QPJ+/!L5%04F`B8Y)HDO'W\51132'Y!```````
M+``````[`$4```?_@&06$H0+AH:$B8J+C(06"X6($H>4AXD++2T+4$PT!9^@
MH:*CI!PZ!S,'!Q$*"B2NL*^R)+2OK1D="!,F(F"^O\#!PL%:635N*#()5VI?
M:L_0T6H-U-0N/0^Z04%)W5W?$.'BX^$`YN,`22(9R"A-:F8G0//T]?9`5]AY
M/`)2`!A"`@;$0+"@08`#"PH9(D6)!AD&EJ1Q<L.)Q8L8Y:E0P8"!BP%A=(G@
M!N'?.7+CO(%+XD5`%R%=6I1(@<+-%!QC<OS9R9/GO0\#LDT8V>6?$`SFDBH]
M]V_($`@"B@!P*L1&!!DHVDQQ,N9>O3%@NP)A$%1D$`@%Q2U5Z@U`%RD2_XKX
M$P(@B(X*4:@,V"/6*Y`_3OC.^RATY#\,X00D^<:X\;;%28+`6$"G*(0@(]I$
MB;(7B(H/H$.'OBB6,`(>0;I@<`H`0I*I3F/'[C85@P`XBI%VH9-G28H44W+<
MT-FS^!\5],@6!J`8@!`(K-$X1U/2+5*T`%KP$Q)$P&H0:PRD"'#B@_$K+OY<
M87`E1PYYRD6F*XGA;%*`2,VI;HWXR`0HW"5!D`]+K)%"&N49]T%Z.7QP17OS
MQ#<48B5)(0(424@A11+E,,5?$D3H`"`WSBVPA`$4J)%@3SFX@%X.#*C@7D<2
MBH`!8S:P,(*.2FP!AA3TE12.$%*\(&)]KPEAP?^)5IQPPAC&53/%%`'@D(,9
M8Y4UE%O?6#!##6LLH0$%.K1P5G5#2C'"D0((X-R2!MB!PY/%N>#"!P&LL`(;
M[<&GI0A)06`!`6U0P`8!:ZQ1P)G_A(-!$AQDP,>C`@YAH@%&W$`GBR[D$(`,
MRN#@@I_+F31H!0=T\((&%61@`W6-0L`="5SP0:2`&'BQ!`5/.-EI3^W]$8`=
M=LCA'I8UT@?`J0>T<,0%5#A@@Z.M06?7#'Q0AZL/:Q`PA9/FL7C%!S@T\(P+
M7Y`J$GT8G!K!!B!<L((#)D#@3[5#!+'#!1M0AY80,+3!1AJ:7E%<>RV:JT)[
MR/[)+K/.4H`'O1"@,43_:U,%04(-1*"%%AIPK&$$>S>,$>Y.#1J<1@!I])EE
M8=1"?`0%\]:[4%%.25'`$B0$`5!=-*3P1+DN`!'6T6,$0(`5,>!PA;I#Q4P`
MJBWX0$$*%,/414E#H/&"&R5L\+$-#A!0)90Q(MW1IRDDX(*F+Z^+'<161Y$U
MHUU[H,$2B[9FP@%VP+.@"DB#EG0*!B0@*M0B2$UUW7=7"Q`6,[2A`192"(!%
M"4^88<88+HQ!>%CCXO!IXCC<$*'#<T]]P`)6U_R2FU`Y9X,.2U2P@P5!$*%!
M`!V-*_K1'#$0``JHW]`PS*U7$$'5%/A!;Q)/50M=$BQH@((&/_#!00GC;H3T
M_]'&0Z2XZG%'W7RS,V-M@@!=7_?Q`A>$Q\4&)92!PP<;J?#'^&,H7_)6QSRD
M,*L.1*"`&S@@@(HII3I!R$`;EI"!/EP@`*#I'U?&)\#S$5!N!IQ:$QPP@RAD
MP`M`:HUJ*(0!*;RA"0880142T`##S6.#:CN=!]/7N.:EP`U-B$,8W"2=;P#$
M-7[+0`F8P(4R!``)=W+2<3BHP]1]4'TAK,`*"%""-5C!`U)8"$'.P2&WD*$`
M/:A!`.(P`#LYR4F>$5\`CS=`'CK."AOX@1L,H`/O/"=0Y>A"$.JP`RNDH0EF
M>UL\5-<_L!@/>3M,UOJ<=0$49*U#X;`8`.@0`@+(8?\`!D"!$5ST-$;*\9%U
ME&06GV<U&4R/.6A"2]?H0`*SQ6"/30C.#>#6R#E"THIV;!XK*6`W$_BCC)*[
MD0UFP`8DG($"!G!##.Z4`^3T$I619%T6FP6Y]\$$38?I`@PT((<]("$&H*)`
M&ES4E6O2,9L%7);K(N:^)-#E@>FP`1>6,(4[(8$`*$!!&=1CS5.^$YBJE"?5
MVC<]NB@K'$$X0@FL$`#TX$`,T+0"%`LZ.FPB5)L*9=_5IH<8<UPG"5"@@0;T
MH(8_X.`/#4!G+O?`44<>%'VJ;-<\&6J"),`J+4DP00EJT+D/M.@C*S"`&.[4
MO]'AZ9<X_9,1=?JX"TCO5:G_*8=3@M`'-XSG`[MT3QK8((-I'@P]QPM55`OS
M#7,,"@7<M*JT;$.AVMA@8WY0PQC"VJ(!R*`)#3BK"](*3_F8B@`&B.M5I>/0
M?Z"A!5QP0P)$Q]<<I"&IZP066I-1V"TU:E`R4"R]D/(<^H"H?B/;Y7#<<X4$
MH""S/'G08#G[T<*D!;3<+('T3&".TOXC"`4`DQA2Q]<KX.`,,@@`<7HR6[4R
M;HR"(D`-GK<``D2A62YIC70@`(8,'&,*#%`M:UTP!3<$(#W`(B]M1\5#I$C'
M`ADX0`868(,,$(`+(-@0&E[C%LJUH0G`$Z][7'#(\S*W10&P`@&:)H_VE@,"
MAW")_Q<T80,.E10`4B#"!?Z;!@:<H+)7^*>!>6+4*S0@#2A.W7-=(YVS=&$(
MS^E&22Q6#CI400/=0@(0!*R>+U`4O3MYT16*M]?EG28(U4+#?IU#E<,0I'H`
M@,(.UD`%*S3@P[O<",(2L$[WN*?$+6+`&*X`M_B@AEVM<=-!#)))*#C@1`E0
MT1OGK(8YR'G.<U[N6$PS`1)!%YEKP=AE#B`>/G7*RPW*P17.<&A$(_IH0#@!
MGT>"EK0$>BG<+4$44L"&+SC!T8IN0#]!_6B3(4?2?SJ+02Y]'P"@P097:UL#
M/NWH#YR8U*5&3J1-@QK[K/G7!4&#"33P&QHVJ*DJ<%J,D/^-;+"HX(TY*`L/
MH$`B)1-$R=C.-AJ0(H4%$#L%5LX@L\>-[(X\VU<]"`D/>&&#=KO[W?!^-Q8N
M8(!NI0$)^,ZWOO?-;WX[`1M,X``I!DZ*"!C<`:U(N,(7SO"&MV(''6!""$*0
MA0Y8_.(8S_C%LU!QBX=`XR`/N<@WL(1CN.%$)Z_!$MRP`C?4P.1A4GDT7^YR
M#6C`Y2_/N<YWSO.=EQS'FZ%)&]8P0?&D0`:)"D\;*K"$-A@@"A-<>@4T0X4*
M6/WJ5V\#%:A@@*Y3F0I(-T#6IT[E*/@A!2O(RQI0\!LJ)$HS:;<Z%:*P@JG+
M8.L5\(,,L,[W9.2E`N')2S(,`*K_J;<!!5$(D]@3)?8*I"`O2Q_ZW-UN`#U5
M'2)53RH*L)X,JS^]#2Y?0M-7((/?[-WIHY^!ZC4P@Q*40/4E,`#K"7`!U[N=
MZ$D?.M&'WH:A$U[J;9#!T$M^@>(C]O`H</L%"+`W`VQA"QM@01\0@(`75&$'
M)M1"![;@@1=<0`,U*('--5#\XI-?3.+7@/B78/[O7X`$3'#`'6I/@1K4?@8=
M4.(%WC""/,"`!E@`62-``A34`ADP"$?0`3K0`TQ@)&$P`DR``%GP`GU``G<0
M(BSP`'?@`$S`!!8X`T1`!"TP`@A0`!KH`&$0!C20!1S0!P^P!3[0`APP`R&P
M.4Q0!36@V0-@T`<@4`1YP`1*L",M``=8D`%;,`)U0`(+H"-Y0`8CB`!]0`1'
MD`4;P`4F,`(>P`%84`<Z\`(%P`%;D`='``,CZ`$C\`,AL@%52`0X>(`.4`)Y
MP`(OD`<@\`9#F`<SX`$ZL`$.X`-2"`)DX`49P`7/IP0_@`5<``8%X`$3L`$F
MP`5<P`%'@`5TR`,P``9;P`$C0`0>\`,P@(954(#,=X-W``,2@`!UH`1],`-9
ML(<.$(!;``-%X`5Y$`((T(1Y4`<L``8<$`(L$(`L<`1O``*Q"`(P\`9O$`@`
!.S\_
`
end
</TEXT>
</DOCUMENT>
</SUBMISSION>
